These findings suggest that cancer cells resist apoptotic cell death, at least in part, through HDAC3-implicated mechanisms, as well as the fact that HDAC3-specific inhibitors in particular will be a new therapeutic strategy for ERα-positive breast cancer. Here, ESR1 is linked to cancer.